GlassScriptPhysician profile
Joseph D Graney
NPI 1225021892
$2,637.74
in general payments reported to CMS, 2019-2025
30 companies · $306 in 2025
The $306 reported for 2025 was more than what 85% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $196 · 2021: $449 · 2022: $465 · 2023: $687 · 2024: $272 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $382.95 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $364.50 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $283.18 | 2021-2025 | |
| Lilly USA, LLC | $220.36 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.27 | 2019-2025 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Pfizer INC. | $180.25 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $153.94 | 2019-2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $148.04 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $98.23 | 2019-2021 | |
| Corium, LLC | $80.67 | 2022-2023 | Azstarys |
| Kowa Pharmaceuticals America, INC. | $60.41 | 2019-2021 | |
| Ibsa Pharma INC. | $50.22 | 2020-2023 | Tirosint, Licart |
| Sanofi Pasteur INC. | $49.37 | 2019-2023 | |
| Seqirus USA INC | $41.23 | 2025 | Fluad, Flucelvax |
| Collegium Pharmaceutical, INC. | $35.74 | 2025 | Jornay Pm |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $31.68 | 2021 | |
| Amgen INC. | $29.16 | 2021-2022 | |
| Almatica Pharma LLC | $23.68 | 2021 | |
| Abbott Laboratories | $22.51 | 2023 | Freestyle Libre 2 |
| Ars Pharmaceuticals Operations, INC. | $20.93 | 2025 | Neffy |
| Exact Sciences Corporation | $19.77 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $19.69 | 2022 | |
| Axsome Therapeutics, INC. | $19.51 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $19.07 | 2024 | Quviviq |
| Shield Therapeutics INC | $17.93 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $17.05 | 2020 | |
| Arbor Pharmaceuticals, INC. | $16.52 | 2021 | |
| Alkermes, INC. | $15.06 | 2023 | Vivitrol |
| Astrazeneca Pharmaceuticals LP | $14.22 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Graney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.